Welcome to our dedicated page for Indivior Pharmaceuticals news (Ticker: INDV), a resource for investors and traders seeking the latest updates and insights on Indivior Pharmaceuticals stock.
Indivior PLC (NASDAQ: INDV) generates a steady flow of news centered on its role in treating opioid use disorder (OUD) and on the performance of its key product, SUBLOCADE. Company updates frequently combine clinical, operational, and financial information, reflecting both its pharmaceutical focus and its status as a Nasdaq-listed small-cap healthcare stock.
News coverage commonly includes earnings releases and financial guidance, where Indivior reports net revenue, SUBLOCADE net revenue, non-GAAP operating expenses, and adjusted EBITDA. These announcements often discuss progress under the Indivior Action Agenda, a multi-year operational roadmap that emphasizes U.S. SUBLOCADE growth, organizational simplification, and margin expansion.
Another major news theme is clinical and real-world evidence for SUBLOCADE and long-acting injectable buprenorphine. Indivior regularly reports results from randomized trials and open-label studies published in journals such as JAMA Network Open, as well as poster presentations at professional meetings. These items detail outcomes such as rapid reductions in opioid use, improved treatment retention, differences between maintenance doses, and associations between adherence and healthcare resource utilization.
Investors and healthcare professionals will also find corporate and strategic announcements, including index inclusions like the S&P SmallCap 600, participation in healthcare investor conferences, and steps in the company’s plan to redomicile from the U.K. to the U.S. Regulatory and legal developments, such as the conclusion of a legacy U.S. Department of Justice resolution agreement, are disclosed through press releases and Form 8-K filings.
This news page aggregates these various updates so readers can track Indivior’s financial performance, strategic initiatives, clinical research outputs, and regulatory milestones related to its OUD-focused pharmaceutical business.
Indivior PLC (Nasdaq/LSE: INDV) has announced its financial results for the quarter ending June 30, 2024. The company has made available its earnings release, investor presentation, and webcast on its official website at www.indivior.com. A live webcast presentation is scheduled for 13:00 BST (8:00 am ET), to be hosted by CEO Mark Crossley. Interested parties can access the presentation through a webcast link or by registering for telephonic participation. The event provides an opportunity for investors and analysts to gain insights into Indivior's Q2 2024 financial performance and potentially discuss future outlook and strategies.
Indivior PLC (Nasdaq/LSE: INDV) has updated its Q2 and FY 2024 financial outlook, reflecting adverse market conditions impacting SUBLOCADE and initial OPVEE adoption. The company expects SUBLOCADE's net revenue (NR) to grow 25% year-over-year (YOY) and adjusted operating income to rise by 12% YOY in FY 2024. Indivior is discontinuing PERSERIS sales and marketing due to financial non-viability, affecting around 130 employees. The company settled a $85 million litigation with Health Care Services Corp, and expects Q2 net revenue to be between $295m-$303m, with SUBLOCADE contributing $188m-$196m. Indivior will host a conference call at 8:00 AM U.S. EDT.
Indivior has published new data comparing the effectiveness of intranasal (IN) nalmefene (OPVEE 2.7mg) and IN naloxone (4 mg) in reversing synthetic opioid overdoses. The study, using a validated translational model, shows that a single dose of OPVEE significantly reduces simulated cardiac arrests caused by fentanyl and carfentanil overdoses compared to naloxone. For instance, a single OPVEE dose reduced the cardiac arrest rate to 12% in chronic opioid users, whereas naloxone reduced it to 47%. Multiple naloxone doses were required to match OPVEE's effectiveness. The simulation involved 2000 virtual patients, highlighting OPVEE's superior performance in reversing overdoses, which is critical given the high rates of synthetic opioid-linked fatalities in the US. These findings could inform better emergency response strategies.
Indivior has initiated dosing of the first subject in a Phase 2 study of INDV-2000, a non-opioid treatment for Opioid Use Disorder (OUD). This double-blind, placebo-controlled trial will assess the safety and efficacy of INDV-2000 over three months in participants with moderate to severe OUD. Supported by an NIH-HEAL grant, the study aims to determine the dose-response relationship for INDV-2000, an orexin-1 receptor antagonist demonstrated to reduce opioid self-administration in animal studies. INDV-2000 offers a potential new treatment option for individuals seeking non-opioid alternatives.
Indivior, a leading addiction treatment company, will host an analyst teach-in event in New York City, confirming its FY 2024 guidance. The company expects net revenue between $1,240m and $1,330m, an 18% increase from FY 2023. SUBLOCADE revenue is projected at $820m to $880m, a 35% rise. OPVEE revenue is anticipated to be $15m to $25m, and PERSERIS revenue is forecasted at $55m to $65m, a 43% increase. SUBOXONE Film market share is expected to decline by 1-2 percentage points. Adjusted gross margin is estimated to be in the low to mid-80s range.
Adjusted SG&A expenses are projected at $575m to $590m, with R&D expenses between $120m and $130m. Adjusted operating profit is expected to be $330m to $380m. The event will be webcast and aims to provide an in-depth overview of Indivior's growth and value creation strategies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Indivior Pharmaceuticals (INDV)?
What is the market cap of Indivior Pharmaceuticals (INDV)?
